A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (NCT06459180)
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
🩺 Plain-English Summary (8th-Grade Level)
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Who can join: Review the eligibility criteria below.
Location: USA Mitchell Cancer Institute-Clinical Trials ( Site 4126) — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (240 Sites)
Showing the first 25 of 240 sites.
- USA Mitchell Cancer Institute-Clinical Trials ( Site 4126) — Mobile, Alabama
- Providence Alaska Medical Center ( Site 4137) — Anchorage, Alaska
- HonorHealth (HH) ( Site 8002) — Phoenix, Arizona
- Arizona Oncology Associates - HOPE ( Site 8001) — Tucson, Arizona
- Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125) — La Jolla, California
- UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105) — Los Angeles, California
- Hoag Memorial Hospital Presbyterian ( Site 4104) — Newport Beach, California
- Mount Sinai Comprehensive Cancer Center ( Site 4143) — Miami Beach, Florida
- Advent Health ( Site 4140) — Orlando, Florida
- Florida Cancer Specialists East ( Site 7001) — West Palm Beach, Florida
- Northside Hospital ( Site 4127) — Atlanta, Georgia
- Georgia Cancer Center at Augusta University ( Site 4112) — Augusta, Georgia
- Lewis Cancer and Research Pavilion ( Site 4114) — Savannah, Georgia
- University Medical Center New Orleans ( Site 4132) — New Orleans, Louisiana
- Willis Knighton Medical Center ( Site 4101) — Shreveport, Louisiana
- The Center of Hope ( Site 4106) — Reno, Nevada
- Holy Name Medical Center ( Site 4117) — Teaneck, New Jersey
- Optimum Clinical Research Group ( Site 4138) — Albuquerque, New Mexico
- Perlmutter Cancer Center NYU Langone Hospital - Long Island ( Site 4145) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121) — New York, New York
- Duke Cancer Institute ( Site 4120) — Durham, North Carolina
- University of Cincinnati Medical Center ( Site 4128) — Cincinnati, Ohio
- The Ohio State University ( Site 4103) — Hilliard, Ohio
- Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116) — Tulsa, Oklahoma
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) — Eugene, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cervical Cancer
- SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study) — Ouagadougou,
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — Boston, Massachusetts
- International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer — Liège,
- Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement — Houston, Texas
- Sexual Health Empowerment for Women's Health — Kansas City, Missouri
- Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique — Houston, Texas
Explore by condition: All Cervical Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.